CTOs on the Move

BrainStorm Cell

www.brainstorm-cell.com

 
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

BrainStorm Cell raised $16M on 07/21/2017

Similar Companies

Hepalife Technologies

Hepalife Technologies is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sorenson Genomics

Sorenson Genomics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Triangle Compounding Pharmacy

Triangle Compounding Pharmacy is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OrthoLive

OrthoLives mission is to leverage telehealth to streamline orthopedic care so practices and businesses can treat patients quickly.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.